Phase II dose escalation study of caspofungin for invasive aspergillosis

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 12, 2011, Pages 5798-5803

  Cornely, O A ^a,b,c   Vehreschild, J J ^a   Vehreschild, M J G T ^a   Wurthwein G ^d   Arenz, D ^b   Schwartz, S ^e   Heussel, C P ^f   Silling, G ^g   Mahne, M ^b   Franklin, J ^a   Harnischmacher, U ^b   Wilkens, A ^a   Farowski, F ^a   Karthaus, M ^h   Lehrnbecher, T ⁱ   Ullmann, A J ^j   Hallek, M ^a,c   Groll, A H ^d  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c University of Cologne   (Germany)

^d UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^g UNIVERSITY OF MÜNSTER   (Germany)

^h Klinikum Neuperlach   (Germany)

ⁱ GOETHE UNIVERSITY   (Germany)

^j JOHANNES GUTENBERG UNIVERSITY   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CASPOFUNGIN;

ACUTE LEUKEMIA; ADULT; ANEMIA; ANOREXIA; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; BLADDER DISEASE; BONE NECROSIS; BRADYCARDIA; CLINICAL ARTICLE; COMPARTMENT MODEL; CYANOSIS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EVALUATION; FEMALE; FEVER; FOLLOW UP; GENDER; HEADACHE; HEART ARRHYTHMIA; HEART VENTRICLE TACHYCARDIA; HEMOPTYSIS; HERPES SIMPLEX; HUMAN; HYPERCALCEMIA; HYPERGLYCEMIA; HYPERKALEMIA; HYPOALBUMINEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; HYPOTENSION; INVASIVE ASPERGILLOSIS; KIDNEY FAILURE; LACTIC ACIDOSIS; LEUKOPENIA; LIVER FAILURE; LIVER FUNCTION TEST; LUNG HEMORRHAGE; LUNG MYCOSIS; LYMPHADENITIS; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MORTALITY; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PSYCHOSIS; SEPSIS; SIDE EFFECT; STEADY STATE; SYNCOPE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; URINARY BLADDER TAMPONADE;

ANTIFUNGAL AGENTS; ASPERGILLOSIS; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ECHINOCANDINS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 81555206683     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05134-11     Document Type: Article

References (26)

1. Arathoon, E. G., et al. 2002. Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases. Antimicrob. Agents Chemother. 46:451-457. (Pubitemid 34087195)
2. Betts, R. F., et al. 2009. A multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis. Clin. Infect. Dis. 48: 1676-1684.
3. Böhme, A., et al. 1999. Diagnosis of systemic fungal infections in hematology. Standard recommendations of the Working Group for Infections in Hematology and Oncology of the German Association for Hematology and Oncology. Dtsch. Med. Wochenschr. 124(Suppl. 1):S24-S30. (In German.)
4. Böhme, A., et al. 2003. Treatment of fungal infections in hematology and oncology-guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann. Hematol. 82(Suppl. 2):S133-S140. (Pubitemid 37265300)
5. Cornely, O. A. 2008. Aspergillus to Zygomycetes: causes, risk factors, prevention, and treatment of invasive fungal infections. Infection 36:296-313.
6. Cornely, O. A., et al. 2011. Efficacy outcomes in a randomized trial of liposomal amphotericin B based on revised EORTC/MSG 2008 definitions of invasive mould disease. Mycoses 54:e449-e455.
7. Cornely, O. A., et al. 2007. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin. Infect. Dis. 44:1289-1297.
8. De Pauw, B., et al. 2008. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin. Infect. Dis. 46:1813-1821.
9. Farowski, F., et al. 2010. Quantitation of azoles and echinocandins in the compartments of peripheral blood by liquid chromatography-tandem mass spectrometry. Antimicrob. Agents Chemother. 54:1815-1819.
10. Greene, R. E., et al. 2007. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin. Infect. Dis. 44:373-379. (Pubitemid 46147619)
11. Groll, A. H., and T. J. Walsh. 2001. Caspofungin: pharmacology, safety and therapeutic potential in superficial and invasive fungal infections. Expert Opin. Investig. Drugs 10:1545-1558. (Pubitemid 32717334)
12. Herbrecht, R., et al. 2002. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med. 347:408-415. (Pubitemid 34851833)
13. Herbrecht, R., et al. 2010. Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Research and Treatment of Cancer study. Bone Marrow Transplant. 45:1227-1233.
14. Link, H., et al. 2003. Antimicrobial therapy of unexplained fever in neutropenic patients. Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann. Hematol. 82(Suppl. 2):S105-S117. (Pubitemid 37265297)
15. Maertens, J., et al. 2006. Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis. Cancer 107:2888-2897. (Pubitemid 44937044)
16. Migoya, E., et al. 2011. Safety and pharmacokinetics of higher doses of caspofungin in healthy adult participants. J. Clin. Pharmacol. 51:202-211.
17. Mora-Duarte, J., et al. 2002. Comparison of caspofungin and amphotericin B for invasive candidiasis. N. Engl. J. Med. 347:2020-2029. (Pubitemid 35461658)
18. National Cancer Institute. 2003. Common toxicity criteria 3.0. NIH, DHHS, Bethesda, MD.
19. Petraitiene, R., et al. 2002. Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: antigenemia. Antimicrob. Agents Chemother. 46:12-23.
20. Stone, J., et al. 2002. Safety and pharmacokinetics of higher doses of caspofungin, abstr. 1417. 42nd Intersci. Conf. Antimicrob. Agents Chemother., San Diego, CA, 26 to 30 September 2002.
21. Ullmann, A. J. 2003. Review of the safety, tolerability, and drug interactions of the new antifungal agents caspofungin and voriconazole. Curr. Med. Res. Opin. 19:263-271. (Pubitemid 36827834)
22. U.S. National Institutes of Health. Accessed 22 August 2011. Anidulafungin plus voriconazole versus voriconazole for the treatment of invasive aspergillosis. www.clinicaltrials.gov identifier: NCT00531479. http://www .clinicaltrials.gov/ct2/show/NCT00531479?term=NCT00531479&rank=1.
23. Villanueva, A., et al. 2001. A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin. Infect. Dis. 33:1529-1535. (Pubitemid 34246147)
24. Villanueva, A., et al. 2002. A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am. J. Med. 113:294-299. (Pubitemid 35287295)
25. Viscoli, C., et al. 2009. An EORTC phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients. J. Antimicrob. Chemother. 64:1274-1281.
26. Walsh, T. J., et al. 2004. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N. Engl. J. Med. 351:1391-1402.